Skip to content
PIL Logo

Fabrazyme 5 mg, powder for concentrate for solution for infusion

Last Updated on eMC 03-Nov-2017 View changes  | Genzyme Therapeutics Contact details

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Please click on the link to the left to view the PIL in PDF format.

Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link to the left. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000. The product code(s) for this leaflet is/are: EU/1/01/188/006, EU/1/01/188/005, EU/1/01/188/004.



Fabrazyme 5 mg, powder for concentrate for solution for infusion

Package leaflet: Information for the user

Fabrazyme 5 mg powder for concentrate for solution for infusion

Agalsidase beta

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Fabrazyme is and what it is used for
2. What you need to know before you use Fabrazyme
3. How to use Fabrazyme
4. Possible side effects
5. How to store Fabrazyme
6. Contents of the pack and other information

1. What Fabrazyme is and what it is used for

Fabrazyme contains the active substance agalsidase beta and is used as enzyme replacement therapy in Fabry disease, where the level of α-galactosidase enzyme activity is absent or lower than normal. If you suffer from Fabry disease a fat substance, called globotriaosylceramide (GL-3), is not removed from the cells of your body and starts to accumulate in the walls of the blood vessels of your organs.

Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.

Fabrazyme is indicated in adults, children and adolescents aged 8 years and older.

2. What you need to know before you use Fabrazyme

Do not use Fabrazyme

  • if you are allergic to agalsidase beta or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before using Fabrazyme.

If you are treated with Fabrazyme, you may develop infusion associated reactions. An infusion-associated reaction is any side effect occurring during the infusion or until the end of the infusion day (see section 4). If you experience a reaction like this, you should tell your doctor immediately. You may need to be given additional medicines to prevent such reactions from occurring.

Children and adolescents

No clinical studies have been performed in children 0-4 years old. The risks and benefits of Fabrazyme in children aged 5 to 7 years have not yet been established and therefore no dose can be recommended for this age group.

Other medicines and Fabrazyme

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Tell your doctor if you use any medicines containing chloroquine, amiodarone, benoquin or gentamicin. There is a theoretical risk of decreased agalsidase beta activity.

Pregnancy, breast-feeding and fertility

Use of Fabrazyme during pregnancy is not recommended. There is no experience with the use of Fabrazyme in pregnant women. Fabrazyme may get into breast milk. Use of Fabrazyme during breast-feeding is not recommended. Studies have not been performed to examine the effects of Fabrazyme on fertility.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

Do not drive or use machines if you experience dizziness, sleepiness, vertigo or fainting during or shortly after administration of Fabrazyme (see section 4). Talk to your doctor first.

3. How to use Fabrazyme

Fabrazyme is given through a drip into a vein (by intravenous infusion). It is supplied as a powder which will be mixed with sterile water before it is given (see information for Health Care Professionals at the end of this leaflet).

Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

Fabrazyme is only used under the supervision of a doctor who is knowledgeable in the treatment of Fabry disease. Your doctor may advise that you can be treated at home provided you meet certain criteria. Please contact your doctor if you would like to be treated at home.

The recommended dose of Fabrazyme for adults is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.

Use in children and adolescents

The recommended dose of Fabrazyme for children and adolescents 8 – 16 years is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.

If you use more Fabrazyme than you should

Doses up to 3 mg/kg body weight have shown to be safe.

If you forget to use Fabrazyme

If you have missed an infusion of Fabrazyme, please contact your doctor.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In clinical studies side effects were mainly seen while patients were being given the medicine or shortly after (“infusion related reactions”). Severe life-threatening allergic reactions (“anaphylactoid reactions”) have been reported in some patients. If you experience any serious side effect, you should contact your doctor immediately.

Very common symptoms (may affect more than 1 in 10 people) include chills, fever, feeling cold, nausea, vomiting, headache and abnormal feelings in the skin such as burning or tingling. Your doctor may decide to lower the infusion rate or give you additional medicines to prevent such reactions from occurring.

List of other side effects:

Common (may affect up to 1 in 10 people):

  • chest pain
  • difficulty in breathing
  • pallor
  • itching
  • abnormal tear secretion
  • feeling weak
  • tinnitus
  • nasal congestion
  • diarrhoea
  • redness
  • muscle pain
  • increased blood pressure
  • sudden swelling of the face or throat
  • oedema in extremities
  • vertigo
  • stomach discomfort
  • muscle spasms
  • sleepiness
  • increased heart beat
  • abdominal pain
  • back pain
  • rash
  • low heart rate
  • lethargy
  • syncope
  • cough
  • abdominal discomfort
  • swelling face
  • joint pain
  • decreased blood pressure
  • chest discomfort
  • face oedema
  • exacerbated difficulty in breathing
  • muscle tightness
  • fatigue
  • flushing
  • pain
  • throat tightness
  • dizziness
  • palpitations
  • decreased sensitivity to pain
  • burning sensation
  • wheezing
  • urticaria
  • pain at the extremities
  • nasopharyngitis
  • hot flush
  • feeling hot
  • hyperthermia
  • decreased mouth sensitivity
  • musculoskeletal stiffness

Uncommon (may affect up to 1 in 100 people):

  • tremor
  • red eyes
  • ear pain
  • throat pain
  • fast breathing
  • itchy rash
  • feeling hot and cold
  • difficulty swallowing
  • infusion site pain
  • infusion site reaction
  • itching eyes
  • ear swelling
  • bronchospasm
  • runny nose
  • heart burn
  • skin discomfort
  • musculoskeletal pain
  • rhinitis
  • influenza-like illness
  • malaise
  • low heart rate due to conduction disturbances
  • increased sensitivity to pain
  • upper respiratory tract congestion
  • red rash
  • (mottled purplish) skin discoloration
  • coldness of the extremities
  • injection site blood clotting
  • skin discoloration
  • oedema

Not known (frequency cannot be estimated from the available data):

  • lower blood oxygen levels
  • serious inflammation of the vessels

In some patients initially treated at the recommended dose, and whose dose was later reduced for an extended period, some symptoms of Fabry disease were reported more frequently.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed below. By reporting side effects you can help provide more information on the safety of this medicine.

United Kingdom

Yellow Card Scheme
Website:www.mhra.gov.uk/yellowcard

Ireland

HPRA Pharmacovigilance
Earlsfort Terrace 4
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website:www.hpra.ie
e-mail:medsafety@hpra.ie

Malta

ADR Reporting
Website:www.medicinesauthority.gov.mt/adrportal

5. How to store Fabrazyme

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after ‘EXP’. The expiry date refers to the last day of that month.

Unopened vials

Store in a refrigerator (2°C – 8°C).

Reconstituted and diluted solutions

The reconstituted solution cannot be stored and should be promptly diluted. The diluted solution can be held for up to 24 hours at 2°C – 8°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Fabrazyme contains

  • The active substance is agalsidase beta, one vial contains 5 mg.
  • The other ingredients are:
    • Mannitol
    • Sodium phosphate monobasic, monohydrate
    • Sodium phosphate dibasic, heptahydrate.

What Fabrazyme looks like and contents of the pack

Fabrazyme is supplied as a white to off-white powder. After reconstitution it is a clear, colourless liquid, free from foreign matter. The reconstituted solution must be further diluted.

Package sizes: 1, 5 and 10 vials per carton. Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing authorisation holder

Genzyme Europe B.V.
Gooimeer 10
1411DD Naarden
The Netherlands

Manufacturer

Genzyme Ltd.
37 Hollands Road
Haverhill
Suffolk
CB9 8PU
United Kingdom

Genzyme Ireland Ltd.
IDA Industrial Park
Old Kilmeaden Road
Waterford
Ireland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Sanofi
Tel: +44 (0)845 372 7101

This leaflet was last revised in October 2017

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.

Certain risk materials on this website are intended for use by healthcare professionals only.

By proceeding you are confirming that you are a healthcare professional.

Want to avoid this message? If you are a Healthcare professional, REGISTER or LOGIN and you will not have to self-certify when you access Risk Minimisation Materials.

You can leave feedback on specific Risk Minimisation Materials or make general observations about how they are displayed on the eMC by leaving comments in the box below.

Please note that we are unable to respond to medical queries.

Fabrazyme 5 mg, powder for concentrate for solution for infusion


Please enter your email address below

Tick here if you wish to recieve a response to your feedback

Risk Materials
VIEW

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Fabrazyme (agalsidase beta) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Fabrazyme (agalsidase beta) at home.

For Healthcare Professionals

Fabrazyme (agalsidase beta) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Fabrazyme (agalsidase beta) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment.

CLOSE THIS PANEL

Company contact details

Genzyme Therapeutics

Company image
Address

4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, Oxfordshire, OX4 2SU

Fax

+44 (0)1865 774 172

Medical Information e-mail
Medical Information Fax

+44 (0)1865 774 172

Telephone

+44 (0)1865 405 200

Medical Information Direct Line

+44 (0)1865 405 283

Customer Care direct line

+44 (0)1865 405 200

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

agalsidase beta

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue